A 28-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222 / MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-012)

Trial Profile

A 28-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222 / MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-012)

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2015

At a glance

  • Drugs Tildrakizumab (Primary) ; Etanercept
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck
  • Most Recent Events

    • 02 Jul 2015 Status changed from suspended to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 30 Dec 2014 Planned End Date changed from 1 Jul 2019 to 1 Aug 2018 as reported by ClinicalTrials.gov.
    • 30 Dec 2014 Planned primary completion date changed from 1 Jul 2019 to 1 Aug 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top